Zoledronic Acid Injection

Category: Bisphosphonate / Bone resorption inhibitor
Form: Injectable solution (intravenous)

Uses:

• Treatment of osteoporosis in postmenopausal women and men at high risk of fracture.

• Management of bone metastases in patients with cancers such as breast cancer, prostate cancer, or multiple myeloma.

• Treatment of Paget’s disease of bone.

• Prevention of skeletal-related events in patients with malignant bone disease.

• Treatment of hypercalcemia of malignancy.

Mechanism of Action:

• Zoledronic acid inhibits osteoclast-mediated bone resorption.

• Binds to hydroxyapatite in bone, reducing osteoclast activity and preventing bone breakdown.

• Helps increase bone mineral density, strengthen bones, and reduce fracture risk.

• Reduces calcium release from bones, lowering elevated blood calcium levels in hypercalcemia.

Administration:

• Administered intravenously, usually as a slow infusion over at least 15 minutes.

• Dosage and frequency depend on indication:

  • Osteoporosis: typically once yearly.

  • Cancer-related bone disease: may be given every 3–4 weeks.

Side Effects:

• Acute-phase reactions: fever, fatigue, muscle or joint pain, flu-like symptoms (usually short-term).

• Electrolyte disturbances: low calcium or phosphate levels.

• Renal effects: potential kidney function impairment; monitor renal function before and during therapy.

• Other: nausea, vomiting, headache, injection site reactions.

• Rare: osteonecrosis of the jaw, atypical femur fractures.

Precautions:

• Ensure adequate hydration before administration.

• Correct low calcium or vitamin D deficiency before therapy.

• Monitor kidney function and adjust dose in renal impairment.

• Avoid in patients with severe renal dysfunction or hypersensitivity to zoledronic acid.

• Dental examination recommended before long-term therapy to reduce risk of jaw osteonecrosis.

Summary:
Zoledronic Acid Injection is a potent bisphosphonate used to inhibit bone resorption, strengthen bones, and reduce fracture risk in osteoporosis, Paget’s disease, and cancer-related bone conditions. Administered intravenously, it can also treat hypercalcemia of malignancy. Side effects include acute-phase reactions, electrolyte disturbances, and rare serious complications such as osteonecrosis of the jaw or kidney impairment, requiring careful monitoring and precautions.